I E Krop
Overview
Explore the profile of I E Krop including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, et al.
Oncogene
. 2025 Jan;
44(7):478-479.
PMID: 39890968
No abstract available.
2.
Freedman R, Heiling H, Li T, Trapani D, Tayob N, Smith K, et al.
Ann Oncol
. 2024 Jul;
35(11):993-1002.
PMID: 38977064
Background: Treatment options for human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases (BCBMs) remain limited. We previously reported central nervous system (CNS) activity for neratinib and neratinib-capecitabine....
3.
Grinshpun A, Ren S, Graham N, DeMeo M, Wrabel E, Carter J, et al.
ESMO Open
. 2024 Jun;
9(6):103465.
PMID: 38833970
Background: In most patients with advanced human epidermal growth factor receptor-2-positive (HER2+) breast cancer, anti-HER2 therapies fail due to the development of acquired resistance, potentially mediated through phosphoinositide-3-kinase (PI3K) signaling....
4.
Marin-Aguilera M, Jares P, Sanfeliu E, Villacampa G, Hernandez-Lllan E, Martinez-Puchol A, et al.
ESMO Open
. 2024 Mar;
9(3):102903.
PMID: 38452436
Background: HER2DX, a multianalyte genomic test, has been clinically validated to predict breast cancer recurrence risk (relapse risk score), the probability of achieving pathological complete response post-neoadjuvant therapy (pCR likelihood...
5.
Parsons H, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, et al.
Ann Oncol
. 2023 Aug;
34(10):899-906.
PMID: 37597579
Background: We aimed to examine circulating tumor DNA (ctDNA) and its association with residual cancer burden (RCB) using an ultrasensitive assay in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant...
6.
Tarantino P, Burstein H, Lin N, Krop I, Winer E, Schnitt S, et al.
Ann Oncol
. 2021 Dec;
33(3):234-238.
PMID: 34942341
No abstract available.
7.
Dent S, Cortes J, Im Y, Dieras V, Harbeck N, Krop I, et al.
Ann Oncol
. 2020 Nov;
32(2):197-207.
PMID: 33186740
Background: The phase III SANDPIPER study assessed taselisib (GDC-0032), a potent, selective PI3K inhibitor, plus fulvestrant in estrogen receptor-positive, HER2-negative, PIK3CA-mutant locally advanced or metastatic breast cancer. Patients And Methods:...
8.
Waks A, Cohen O, Kochupurakkal B, Kim D, Dunn C, Buendia Buendia J, et al.
Ann Oncol
. 2020 Apr;
31(5):590-598.
PMID: 32245699
Background: Little is known about mechanisms of resistance to poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) and platinum chemotherapy in patients with metastatic breast cancer and BRCA1/2 mutations. Further investigation of resistance...
9.
Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick A, et al.
Ann Oncol
. 2019 Mar;
30(6):927-933.
PMID: 30903140
Background: HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2...
10.
Barroso-Sousa R, Barry W, Guo H, Dillon D, Tan Y, Fuhrman K, et al.
Ann Oncol
. 2019 Feb;
30(4):575-581.
PMID: 30753274
Background: Previous data suggest that the immune microenvironment plays a critical role in human epidermal growth factor receptor 2 (HER2) -positive breast cancer; however, there is little known about the...